BPFOPHA@EC2611A

Fosun Pharma Announces First Patient Dosed in China Phase I Trial for Innovative Drug FXB0871

Yoyou Pharma Granted Exclusive Rights for GR1803 by ZhiXiang JinTai in China

Henlius: First Patient Dosed in International Phase 2/3 Study of HLX43 Alone or Combined with HLX07 for NSCLC Treatment

Fosun Pharmaceutical's Subsidiary Joins with Multiple Parties to Establish 1 Billion Yuan Hangzhou Fund

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

Fosun Pharma: Expected to submit NDA by year-end

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

Fosun Pharma subsidiary obtains approval for Sodium Nitroprusside Injection registration

Fosun High-Tech Reports 9.1% Q1 Revenue Growth

Fosun Pharma Signs Strategic MOU with Arcera

Fosun Pharma Subsidiary Obtains EU Approval for Pertuzumab Injection

FOSUN PHARMA released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue HKD 11.42 B (forecast HKD 11.16 B), actual EPS HKD 0.3741 (forecast HKD 0.0226)

Fosun Pharma Reports Revenue and Net Profit Growth for Q1 2026

Morgan Stanley Raises Revenue Forecast for Fosun Pharma and Provides Stock Price Target

FOSUN PHARMA to release FY2026 Q1 earnings on April 28 After-Market (BJT), forecast revenue HKD 11.18 B, EPS HKD 0.0227

Fosun Pharma Announces 2025 Annual Report with 29.6% Growth in Innovative Drug Revenue

JOLIMARK

TIMES UNI GP

APEX ACE HLDG

VPOWER GROUP

GW TIANDI

FUJING HOLDINGS

TEAMWAY INTL GP

SFSY NEW MAT

FDB HOLDINGS

KEEN OCEAN

02196

600196

520880

516930

512290

516500

159849

512010

588130

510660

China's biotech sector is experiencing significant growth, with 15 out of 19 innovative drugs approved by the National Medical Products Administration (NMPA) this year coming from domestic companies. The approval process has been streamlined to support local innovation, and R&D spending is increasing, exemplified by Fosun Pharma's 4.3 billion yuan investment. In Q1 2026, Chinese biotech firms secured a record US$60 billion in cross-border licensing deals, highlighting the need for global pharmaceutical companies to develop strategies for the Chinese market.

SCMP

FOSUN PHARMA

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Beigene

ING Groep

China’s biotech boom drives surge in home-grown innovative drug approvals

00656

Fosun International Included in S&P Global Sustainability Yearbook (China Edition) 2026, Maintains Top 1% Ranking for Third Consecutive Year | FOSUF Stock News

StockTitan

FOSUN INTL

S&P Global

Fosun International Included in S&P Global Sustainability Yearbook (China Edition) 2026, Maintains Top 1% Ranking for Third Consecutive Year | FOSUF Stock News

Fosun Pharma and AriBio have signed an exclusive global option agreement for AR1001, a drug candidate for Alzheimer's disease. Fosun will pay AriBio a $60 million option fee and up to $180 million in milestone payments upon exercising the option. AR1001 is currently in a Phase 3 trial and has shown potential therapeutic benefits. This partnership expands their previous collaboration to global markets, aiming to accelerate the drug's development and commercialization.

PR Newswire

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease

Shanghai Fosun Pharmaceutical's subsidiary, Fosun Pharma (Xuzhou), has received approval from China's National Medical Products Administration to market Venlafaxine Hydrochloride Sustained-release Tablets, a Class 3 drug for treating depression and anxiety disorders. This approval enhances Fosun Pharma's central nervous system portfolio and competitive position in the antidepressant market. The subsidiary will act as both the marketing authorization holder and manufacturer, supporting revenue diversification. Analysts rate the stock (HK:2196) as a Buy with a target price of HK$35.30.

Tip Ranks

Fosun Pharma Subsidiary Wins China Approval for Venlafaxine SR Tablets

BPFOPHA@EC2611A(29567.HK)

China’s biotech boom drives surge in home-grown innovative drug approvals

Fosun International Included in S&P Global Sustainability Yearbook (China Edition) 2026, Maintains Top 1% Ranking for Third Consecutive Year | FOSUF Stock News

Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease

Fosun Pharma Subsidiary Wins China Approval for Venlafaxine SR Tablets